Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ssr-150106 SCHEMBL29393331 | 1.00 | SIGMAR1 (0.48) | SIGMAR1PPARGPPARAHTR7PARP1 | |
| SCHEMBL6590514 | 0.96 | SIGMAR1 (0.48) | SIGMAR1PPARGPPARAHTR7PARP1 | |
| Ssr-150106 SCHEMBL3078311 | 0.91 | PPARG (0.44) | SIGMAR1PPARGPPARAHTR7PARP1 | |
| SCHEMBL6587088 | 0.90 | SIGMAR1 (0.52) | SIGMAR1PPARGPPARAPARP1KDM4E | |
| SCHEMBL5149448 | 0.89 | PPARG (0.47) | SIGMAR1PPARGPPARAHTR7PARP1 | |
| Xaliproden SCHEMBL1650254 | 0.88 | SIGMAR1 (0.52) | SIGMAR1PPARGPPARAHTR7PARP1 | |
| Xaliproden SCHEMBL137094 | 0.88 | SIGMAR1 (0.51) | SIGMAR1PPARGPPARAHTR7PARP1 | |
| Xaliproden SCHEMBL29377982 | 0.88 | SIGMAR1 (0.51) | SIGMAR1PPARGPPARAHTR7PARP1 | |
| SCHEMBL6589537 | 0.87 | SIGMAR1 (0.51) | SIGMAR1HTR7PARP1DRD2DRD4 | |
| Xaliproden SCHEMBL29393004 | 0.87 | SIGMAR1 (0.50) | SIGMAR1PPARGPPARAHTR7PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4831908-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-7795277-B2 | 7-(2-(4-(3-trifuloromethyl-phenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isoquinoline besylate salt, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | claimed |
| EP-1861389-B1 | 7-(2-(4-(3-TRIFLUOROMETHYL-PHENYL)-1,2,3,6-TETRAHYDRO-PYRID-1-YL)ETHYL) ISOQUINOLINE BESYLATE SALT, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-06-25 | — | — | EP | claimed |
| US-20080085917-A1 | 7-(2-(4-(3-TRIFLUOROMETHYL-PHENYL)-1,2,3,6-TETRAHYDROPYRID-1-YL)ETHYL)ISOQUINOLINE BESYLATE SALT, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-04-10 | — | — | US | claimed |
| EP-1861389-A1 | 7-(2-(4-(3-TRIFLUOROMETHYL-PHENYL)-1,2,3,6-TETRAHYDRO-PYRID-1-YL)ETHYL) ISOQUINOLINE BESYLATE SALT, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097624-A1 | 7-(2-(4-(3-TRIFLUOROMETHYL-PHENYL)-1,2,3,6-TETRAHYDRO-PYRID-1-YL)ETHYL) ISOQUINOLINE BESYLATE SALT, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-09-21 | — | — | WO | claimed |
| EP-1226137-B8 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | claimed |
| EP-1226137-B1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI SYNTHELABO (FR) | 2004-07-21 | — | — | EP | claimed |
| US-6509351-B1 | A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation | SANOFI-SYNTELABO (FR) | 2003-01-21 | — | — | US | claimed |
| EP-1226137-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2002-07-31 | — | — | EP | claimed |
| WO-2001029026-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2001-04-26 | — | — | WO | claimed |
| EP-1383761-B1 | Phenyl- and pyridyl-piperidines with tnf activity | SANOFI AVENTIS (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-7795277-B2 | 7-(2-(4-(3-trifuloromethyl-phenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isoquinoline besylate salt, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-7795277-B2 | 7-(2-(4-(3-trifuloromethyl-phenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isoquinoline besylate salt, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-7795277-B2 | 7-(2-(4-(3-trifuloromethyl-phenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isoquinoline besylate salt, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| EP-1383761-A1 | PHENYL- AND PYRIDYL-PIPERIDINES WITH TNF ACTIVITY | Sanofi-Aventis (FR) | 2004-01-28 | — | — | EP | disclosed |
| US-6509351-B1 | A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation | SANOFI-SYNTELABO (FR) | 2003-01-21 | — | — | US | disclosed |
| WO-2002085887-A1 | PHENYL- AND PYRIDYL-PIPERIDINES WITH TNF ACTIVITY | SANOFI-SYNTHELABO (FR) | 2002-10-31 | — | — | WO | disclosed |
| EP-1226137-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001029026-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085917-A1 | 7-(2-(4-(3-TRIFLUOROMETHYL-PHENYL)-1,2,3,6-TETRAHYDROPYRID-1-YL)ETHYL)ISOQUINOLINE BESYLATE SALT, PREPARATION AND THERAPEUTIC USE THEREOF | SCN7A, SLC10A1, REN | SIGMAR1 1247/4885PPARG 2321/4885PPARA 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.